Recent News Releases
Latest CSL News
UQ, CEPI and CSL partner for COVID-19
• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate
• CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate
• A vaccine is anticipated to be available in 2021 if clinical trials are successful
2021 CSL Centenary Fellowships
Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.
CSL’s Global Role in Battling COVID-19
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19
Development of COVID-19 immunoglobulin commences
Plasma-derived therapeutic with potential to treat serious complications of COVID-19.
CSL Behring and SAB Biotherapeutics Join Forces
King of Prussia, Pa. and Sioux Falls, S.D.
COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer
Collaborating on Potential COVID-19 Therapy
Osaka, JAPAN, and King of Prussia, PA, USA
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Our Offer To Help Battle Coronavirus
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
CSL Ranks Among Best Employers for Diversity
Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.
CSL at J.P. Morgan's 2020 Healthcare Conference
Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
CSL Continues to Advance R&D Capabilities
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.
CSL Media Statement
CSL statement in response to media reports on case against Joseph Chiao
CSL Limited Celebrates 25 Years on the ASX
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.
$2.5 million CSL Centenary Fellowships announced
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.
CSL to Move Global Headquarters
Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination
CSL Names Paul McKenzie as Chief Operating Officer
Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
CSL Renews Partnership with NYSF
MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long STEM literacy.
Nancy Millis building opens at Bio21 Institute
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, incorporating CSL’s Global Hub for Research and Translational Medicine.
Senior Manager, Communications
Phone: +61 429 609 762